Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET


SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.

Dial-in Number 
U.S. / Canada Dial-in Number: 888-330-3556
International Dial-in Number: 646-960-0826
Conference Call ID: 1816377

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1816377

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:

Investors           

Media                           

Traci McCarty 

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558                     

(650) 374-2803

                       

SOURCE BioMarin Pharmaceutical Inc.


These press releases may also interest you

at 02:36
Photocure ASA: Results for the first quarter of 2024
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost...

at 02:35
MERIL Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT, Presented at EuroPCR 2024 - Earns Prestigious Late Breaking Trial Status & The LANCET Acceptance
Exciting news from Meril Life Sciences! The LANDMARK trial's 30 days primary outcomes were presented on 15th May at EuroPCR 2024, Paris, France. LANDMARK was...

at 02:29
Implantica publishes Interim Report January - March 2024 (Q1)
RefluxStoptm on path to become standard of care for acid reflux treatment Significant events in the first quarter of 2024 Submitted Premarket Approval (PMA) application for RefluxStoptm to U.S. FDA First of three modules submittedNext two modules to...

at 02:05
Cognite Data Fusion® Now Available on Google Cloud in Saudi Arabia
Cognite, a globally recognized leader in industrial software, announced today that its flagship Industrial DataOps product, Cognite Data Fusion®, is now available on Google Cloud in Saudi Arabia. This strategic collaboration combines Cognite's...

at 02:01
Qualcomm will be delivering a keynote speech at COMPUTEX 2024, sharing insights on "The PC Reborn" showcasing where innovation creates disruption in a mature industry
TAITRA (Taiwan External Trade Development Council) announced today that Cristiano Amon, President and CEO of Qualcomm Incorporated, is invited to be the speaker at the COMPUTEX 2024 Keynote. The keynote will be on June 3, 2024, at 1:30 p.m. (UCT+8)...

at 02:00
Novo Holdings to acquire majority stake in Single Use Support
Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital. Founded in 2017 in...

More news about Science and technology...


News published on and distributed by: